INDV Stock Recent News

Indivior's turnaround is driven by SUBLOCADE's strong growth, improved cash flow, and a three-phase recovery plan that the market undervalues. Q2 2025 results beat expectations, with SUBLOCADE delivering 9% YoY growth and management raising full-year revenue and EBITDA guidance. Key risks include heavy reliance on SUBLOCADE, legacy product erosion, and execution risk as the company transitions and optimizes operations.

Indivior (INDV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FFIV, INDV and NVT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 5, 2025.

ARMN, QUAD, NVST, INDV and BJRI have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2025.

Indivior PLC (NASDAQ:INDV ) Q2 2025 Earnings Conference Call July 31, 2025 8:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Joseph J. Ciaffoni - CEO & Director Patrick A.

Indivior PLC (INDV) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.44 per share a year ago.

Q2'25 Total Net Revenue of $302m; Q2'25 SUBLOCADE® Net Revenue of $209m, up 9% Year-over-Year Indivior Action Agenda Underway to Strengthen Business and Generate Operational Momentum Conference Call Scheduled for Today at 8:00 A.M. EDT RICHMOND, Va.

SLOUGH, United Kingdom and RICHMOND, Va. , July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV) today announces that: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List of the UK Financial Conduct Authority; and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's  main market for listed securities, have now been cancelled with effect from 08:00 a.m.

Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD) The study indicates BUP-XR may be an important tool in reducing ED visits, improving healthcare resource utilization and patient outcomes RICHMOND, Va., July 23, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports, which examined demographic and clinical factors associated with ED visits among adults diagnosed with opioid use disorder (OUD) over a six-month follow-up period.

RICHMOND, Va. , July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m.